Clinical Trial Update: A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the effect of Zelicapavir (EDP-938) on the QTc interval in healthy adults, with RSV infection listed as a condition; the trial is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Zelicapavir (EDP-938)

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: RSV Infection, QTc Interval | Phase 1 | Status: COMPLETED